Literature DB >> 34992980

Overlapping NMDA-R and GFAP Antibody Autoimmune Encephalitis After Nivolumab Therapy.

Felipe A Ayala1, Sean C Dougherty1, William Swift1, David A Lapides1.   

Abstract

Entities:  

Year:  2021        PMID： 34992980      PMCID： PMC8723965          DOI： 10.1212/CPJ.0000000000001008

Source DB:  PubMed          Journal:  Neurol Clin Pract        ISSN： 2163-0402


× No keyword cloud information.
  12 in total

1.  Association of Autoimmune Encephalitis With Combined Immune Checkpoint Inhibitor Treatment for Metastatic Cancer.

Authors:  Tanya J Williams; David R Benavides; Kelly-Ann Patrice; Josep O Dalmau; Alexandre Leon Ribeiro de Ávila; Dung T Le; Evan J Lipson; John C Probasco; Ellen M Mowry
Journal:  JAMA Neurol       Date:  2016-08-01       Impact factor: 18.302

Review 2.  Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential.

Authors:  Padmanee Sharma; James P Allison
Journal:  Cell       Date:  2015-04-09       Impact factor: 41.582

3.  Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline.

Authors:  Julie R Brahmer; Christina Lacchetti; Bryan J Schneider; Michael B Atkins; Kelly J Brassil; Jeffrey M Caterino; Ian Chau; Marc S Ernstoff; Jennifer M Gardner; Pamela Ginex; Sigrun Hallmeyer; Jennifer Holter Chakrabarty; Natasha B Leighl; Jennifer S Mammen; David F McDermott; Aung Naing; Loretta J Nastoupil; Tanyanika Phillips; Laura D Porter; Igor Puzanov; Cristina A Reichner; Bianca D Santomasso; Carole Seigel; Alexander Spira; Maria E Suarez-Almazor; Yinghong Wang; Jeffrey S Weber; Jedd D Wolchok; John A Thompson
Journal:  J Clin Oncol       Date:  2018-02-14       Impact factor: 44.544

Review 4.  Inflammatory Manifestations of Systemic Diseases in the Central Nervous System.

Authors:  David A Lapides; Mark M McDonald
Journal:  Curr Treat Options Neurol       Date:  2020-07-29       Impact factor: 3.598

5.  Pembrolizumab-induced autoimmune encephalitis in a patient with advanced non-small cell lung cancer: A case report.

Authors:  Maiko Niki; Aya Nakaya; Takayasu Kurata; Kahori Nakahama; Hiroshige Yoshioka; Toshihiko Kaneda; Kayoko Kibata; Makoto Ogata; Shosaku Nomura
Journal:  Mol Clin Oncol       Date:  2018-11-27

6.  Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab.

Authors:  Ronak K Kapadia; Douglas E Ney; Markus Hannan; Morgan Farley; Daniel M Pastula; Amanda L Piquet
Journal:  J Neuroimmunol       Date:  2020-05-07       Impact factor: 3.478

7.  Severe neurological toxicity of immune checkpoint inhibitors: growing spectrum.

Authors:  Divyanshu Dubey; William S David; Kerry L Reynolds; Donald F Chute; Nathan F Clement; Justine V Cohen; Donald P Lawrence; Meghan J Mooradian; Ryan J Sullivan; Amanda C Guidon
Journal:  Ann Neurol       Date:  2020-02-22       Impact factor: 10.422

8.  PD-1 Checkpoint Inhibitor Associated Autoimmune Encephalitis.

Authors:  Stephanie Schneider; Silke Potthast; Paul Komminoth; Guido Schwegler; Steffen Böhm
Journal:  Case Rep Oncol       Date:  2017-05-24

Review 9.  Autoimmune glial fibrillary acidic protein astrocytopathy.

Authors:  Amy Kunchok; Anastasia Zekeridou; Andrew McKeon
Journal:  Curr Opin Neurol       Date:  2019-06       Impact factor: 5.710

10.  Immune-Checkpoint-Inhibitor-Induced Severe Autoimmune Encephalitis Treated by Steroid and Intravenous Immunoglobulin.

Authors:  Ahwon Kim; Bhumsuk Keam; Hyeon Cheun; Soon Tae Lee; Hyung Seok Gook; Moon Ku Han
Journal:  J Clin Neurol       Date:  2019-03-11       Impact factor: 3.077
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.